Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.